Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML Read more about Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Read more about Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Agios Announces Pricing of $150 Million Public Offering of Common Stock Read more about Agios Announces Pricing of $150 Million Public Offering of Common Stock
Agios Announces Proposed Offering of Common Stock Read more about Agios Announces Proposed Offering of Common Stock
Agios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016 Read more about Agios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016
Agios Appoints Andrew Hirsch as Chief Financial Officer Read more about Agios Appoints Andrew Hirsch as Chief Financial Officer
Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016 Read more about Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
Agios Reports Second Quarter 2016 Financial Results Read more about Agios Reports Second Quarter 2016 Financial Results
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016 Read more about Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency Read more about AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency